gastroesophageal junction adenocarcinoma (Cancer)
Information
- Disease name
- gastroesophageal junction adenocarcinoma
- Disease ID
- DOID:4944
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03760822 | Active, not recruiting | Phase 2 | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients | November 16, 2018 | September 2024 |
| NCT05419362 | Active, not recruiting | Phase 2 | GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer | April 7, 2022 | December 2024 |
| NCT05394740 | Active, not recruiting | Phase 1/Phase 2 | Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | June 6, 2022 | November 2025 |
| NCT05311176 | Active, not recruiting | Phase 2 | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) | August 17, 2022 | July 1, 2026 |
| NCT05203627 | Active, not recruiting | N/A | Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery | January 21, 2020 | December 30, 2024 |
| NCT05008783 | Active, not recruiting | Phase 3 | A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma | September 17, 2021 | April 14, 2025 |
| NCT04772989 | Active, not recruiting | Phase 1 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | March 19, 2021 | September 2025 |
| NCT04661150 | Active, not recruiting | Phase 2 | A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction | March 12, 2021 | August 30, 2026 |
| NCT04499924 | Active, not recruiting | Phase 2/Phase 3 | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer | March 22, 2021 | March 31, 2027 |
| NCT03170960 | Active, not recruiting | Phase 1/Phase 2 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | September 5, 2017 | August 2024 |
| NCT04375605 | Active, not recruiting | Phase 3 | Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ | June 3, 2020 | December 2025 |
| NCT04344795 | Active, not recruiting | Phase 1 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | May 6, 2020 | October 1, 2024 |
| NCT03429816 | Active, not recruiting | N/A | OPPOSITE: Outcome Prediction Of Systemic Treatment in Esophagogastric Carcinoma | April 15, 2018 | November 2023 |
| NCT03979131 | Active, not recruiting | Phase 2 | Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) | August 22, 2019 | June 15, 2026 |
| NCT03852251 | Active, not recruiting | Phase 1/Phase 2 | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma | January 18, 2019 | August 31, 2023 |
| NCT03615326 | Active, not recruiting | Phase 3 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | October 5, 2018 | December 30, 2024 |
| NCT03686488 | Active, not recruiting | Phase 2 | TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | December 20, 2018 | July 1, 2024 |
| NCT03724851 | Active, not recruiting | Phase 1/Phase 2 | Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer | December 20, 2018 | August 31, 2024 |
| NCT02443883 | Completed | Phase 2 | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | July 7, 2015 | June 5, 2019 |
| NCT04808791 | Completed | Phase 2 | iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | October 27, 2021 | July 21, 2023 |
| NCT02539225 | Completed | Phase 2 | A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | October 5, 2015 | March 10, 2021 |
| NCT02572687 | Completed | Phase 1 | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | February 19, 2016 | January 13, 2021 |
| NCT02589496 | Completed | Phase 2 | Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis | March 26, 2016 | December 2021 |
| NCT02628951 | Completed | Phase 2 | Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis | May 26, 2016 | January 2, 2019 |
| NCT02730546 | Completed | Phase 1/Phase 2 | Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery | June 24, 2016 | October 31, 2023 |
| NCT02830594 | Completed | Phase 2 | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | October 5, 2016 | January 16, 2024 |
| NCT02864381 | Completed | Phase 2 | Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma | September 1, 2016 | August 23, 2019 |
| NCT02891447 | Completed | Phase 2 | Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer | September 1, 2016 | April 11, 2023 |
| NCT02898077 | Completed | Phase 3 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | March 2, 2017 | April 12, 2021 |
| NCT04208958 | Completed | Phase 1/Phase 2 | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer | January 23, 2020 | February 23, 2023 |
| NCT04161781 | Completed | A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer | November 12, 2019 | March 6, 2024 | |
| NCT04609813 | Completed | Esophageal cAncer Screening Trial | January 1, 2021 | June 30, 2022 | |
| NCT03083613 | Completed | Phase 2 | Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma | May 2015 | December 1, 2018 |
| NCT00515411 | Completed | Phase 2 | Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma | October 23, 2006 | October 26, 2018 |
| NCT03395847 | Completed | Early Phase 1 | Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma | February 9, 2018 | January 27, 2023 |
| NCT01196390 | Completed | Phase 3 | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | February 14, 2011 | August 15, 2023 |
| NCT03986502 | Completed | N/A | Financial Navigation Intervention in Improving Financial and Clinical Outcomes in Patients With Newly Diagnosed Gastric or Gastroesophageal Junction Adenocarcinoma | January 22, 2021 | October 1, 2022 |
| NCT01962246 | Completed | Phase 2/Phase 3 | Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction | February 2012 | August 2021 |
| NCT03894618 | Completed | Phase 1 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | March 26, 2019 | May 4, 2023 |
| NCT02077673 | Completed | Gastric Microperfusion in Patients Undergoing Gastroesophageal Resections | December 2013 | April 2015 | |
| NCT02082210 | Completed | Phase 1/Phase 2 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | March 7, 2014 | January 24, 2018 |
| NCT02128243 | Completed | Phase 2 | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer | September 2014 | October 8, 2020 |
| NCT03196232 | Completed | Phase 2 | Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer | September 13, 2017 | May 29, 2018 |
| NCT02514551 | Completed | Phase 2 | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | October 12, 2015 | December 28, 2018 |
| NCT02314117 | Completed | Phase 3 | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer | January 20, 2015 | August 14, 2020 |
| NCT02335411 | Completed | Phase 2 | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | February 3, 2015 | July 23, 2021 |
| NCT02370498 | Completed | Phase 3 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | May 11, 2015 | June 10, 2021 |
| NCT02389751 | Completed | Phase 1 | Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer | April 10, 2015 | July 16, 2019 |
| NCT03802591 | Completed | Phase 3 | A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma | March 28, 2019 | September 22, 2023 |
| NCT02307812 | No longer available | Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France | |||
| NCT06454435 | Not yet recruiting | Phase 2 | Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer | June 2024 | June 2027 |
| NCT05111444 | Not yet recruiting | Phase 2 | Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | December 31, 2021 | June 30, 2024 |
| NCT05678205 | Not yet recruiting | Phase 1/Phase 2 | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | August 1, 2023 | April 2027 |
| NCT06196697 | Not yet recruiting | Phase 2 | AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer | January 2024 | March 2027 |
| NCT06341647 | Not yet recruiting | Phase 1 | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | August 31, 2024 | February 2029 |
| NCT05472857 | Recruiting | Phase 1 | Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression | August 8, 2022 | December 2024 |
| NCT05567835 | Recruiting | Phase 2 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer | March 6, 2024 | January 2029 |
| NCT06349044 | Recruiting | N/A | A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. | March 20, 2024 | December 31, 2025 |
| NCT05709574 | Recruiting | Phase 2 | Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer | April 20, 2023 | May 2025 |
| NCT05753306 | Recruiting | Phase 2 | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | March 16, 2023 | February 1, 2026 |
| NCT05802056 | Recruiting | Phase 1 | Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis | November 29, 2023 | January 2026 |
| NCT05836584 | Recruiting | Phase 2 | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer | December 6, 2023 | October 31, 2027 |
| NCT05902988 | Recruiting | Phase 1/Phase 2 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | October 18, 2023 | June 2026 |
| NCT05918419 | Recruiting | Phase 2 | Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction | February 1, 2023 | September 1, 2024 |
| NCT06028737 | Recruiting | Phase 2/Phase 3 | Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer | August 25, 2023 | December 2031 |
| NCT06038578 | Recruiting | Phase 2 | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | October 4, 2023 | August 31, 2025 |
| NCT06047379 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | November 1, 2023 | August 31, 2026 |
| NCT06266299 | Recruiting | Phase 1 | A Study of KK2269 in Adult Participants With Solid Tumors | January 25, 2024 | December 2027 |
| NCT06265285 | Recruiting | Phase 2 | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | March 13, 2024 | December 31, 2026 |
| NCT04290806 | Recruiting | Registry Platform Gastric/Esophageal Cancer (SAPHIR) | December 4, 2019 | December 31, 2024 | |
| NCT06243757 | Recruiting | A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers | January 8, 2024 | January 8, 2036 | |
| NCT04361708 | Recruiting | Phase 1 | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies | May 8, 2020 | May 2027 |
| NCT03175224 | Recruiting | Phase 2 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | September 27, 2017 | November 30, 2026 |
| NCT04389632 | Recruiting | Phase 1 | A Study of SGN-B6A in Advanced Solid Tumors | June 8, 2020 | October 31, 2028 |
| NCT04447352 | Recruiting | Phase 3 | HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) | December 17, 2020 | May 1, 2027 |
| NCT04018872 | Recruiting | Phase 2 | Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer | June 24, 2019 | September 29, 2026 |
| NCT04510129 | Recruiting | A Multicenter Cancer Biospecimen Collection Study | February 5, 2020 | February 2027 | |
| NCT05476796 | Recruiting | Phase 2 | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer | June 23, 2023 | January 2027 |
| NCT04581473 | Recruiting | Phase 1/Phase 2 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | October 23, 2020 | June 30, 2038 |
| NCT06340711 | Recruiting | Phase 2 | Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma | April 25, 2024 | April 2028 |
| NCT04615013 | Recruiting | Phase 1 | NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer | November 23, 2020 | October 31, 2025 |
| NCT04656041 | Recruiting | Phase 2 | Folfox+Irinotecan+Chemort In Esophageal Cancer | June 29, 2021 | December 2027 |
| NCT02962063 | Recruiting | Phase 1/Phase 2 | Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer | November 2016 | November 2024 |
| NCT03421288 | Recruiting | Phase 2 | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness | September 14, 2018 | December 31, 2027 |
| NCT04704934 | Recruiting | Phase 3 | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | May 21, 2021 | February 1, 2026 |
| NCT04762953 | Recruiting | Phase 2 | Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis | February 18, 2021 | June 2025 |
| NCT06221748 | Recruiting | Phase 2/Phase 3 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | February 22, 2024 | December 2027 |
| NCT04805307 | Recruiting | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 | December 24, 2020 | October 2024 |
| NCT04140526 | Recruiting | Phase 1/Phase 2 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | September 16, 2020 | December 31, 2027 |
| NCT04850729 | Recruiting | Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. | May 25, 2021 | April 1, 2026 | |
| NCT06206733 | Recruiting | Phase 3 | ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma | January 25, 2024 | December 30, 2028 |
| NCT04152499 | Recruiting | Phase 1/Phase 2 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies | February 28, 2020 | December 2025 |
| NCT05002127 | Recruiting | Phase 2/Phase 3 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | January 15, 2022 | August 2028 |
| NCT06324357 | Recruiting | Phase 1/Phase 2 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | May 23, 2024 | August 21, 2028 |
| NCT06206278 | Recruiting | Phase 2 | Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma | October 19, 2023 | December 2025 |
| NCT05034887 | Recruiting | Phase 2 | Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma | January 31, 2022 | March 31, 2025 |
| NCT05052801 | Recruiting | Phase 3 | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | March 7, 2022 | August 18, 2025 |
| NCT06353152 | Recruiting | Phase 1 | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma | November 17, 2023 | November 16, 2025 |
| NCT05111626 | Recruiting | Phase 3 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer | March 14, 2022 | September 26, 2026 |
| NCT05156866 | Recruiting | Phase 1 | First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer | February 2, 2022 | January 15, 2026 |
| NCT05159440 | Recruiting | Phase 1 | First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer | January 20, 2022 | December 15, 2025 |
| NCT06157892 | Recruiting | Phase 1/Phase 2 | A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors | May 20, 2024 | January 31, 2030 |
| NCT06155383 | Recruiting | Phase 2 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | November 27, 2023 | December 31, 2027 |
| NCT05334069 | Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | August 1, 2022 | February 2025 | |
| NCT05393986 | Recruiting | Phase 1 | Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors | August 4, 2022 | December 30, 2024 |
| NCT06131840 | Recruiting | Phase 1 | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | November 20, 2023 | March 31, 2030 |
| NCT06121700 | Recruiting | Phase 2 | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer | January 1, 2023 | December 31, 2027 |
| NCT03604991 | Suspended | Phase 2/Phase 3 | Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery | May 3, 2019 | January 31, 2026 |
| NCT02952989 | Terminated | Phase 1 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | February 23, 2017 | June 24, 2019 |
| NCT03511222 | Terminated | Phase 1 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | September 11, 2018 | May 28, 2020 |
| NCT04032704 | Terminated | Phase 2 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | October 9, 2019 | November 28, 2023 |
| NCT04060342 | Terminated | Phase 1 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | August 13, 2019 | April 11, 2022 |
| NCT04089904 | Terminated | Phase 2 | Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma | October 11, 2019 | March 11, 2023 |
| NCT03122548 | Terminated | Phase 2 | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers | August 14, 2017 | January 31, 2018 |
| NCT04510285 | Terminated | Phase 2 | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection | August 10, 2020 | December 30, 2022 |
| NCT03019588 | Terminated | Phase 3 | Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) | February 16, 2017 | June 29, 2021 |
| NCT04683939 | Terminated | Phase 1/Phase 2 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | January 18, 2022 | July 24, 2023 |
| NCT02530437 | Terminated | Phase 1/Phase 2 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer | March 7, 2017 | January 7, 2022 |
| NCT04933227 | Terminated | Phase 2 | A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) | August 6, 2021 | November 17, 2023 |
| NCT02391038 | Terminated | Phase 1 | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C | December 2014 | October 2015 |
| NCT03735290 | Terminated | Phase 1 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer | January 14, 2019 | December 3, 2021 |
| NCT03707028 | Terminated | Phase 1/Phase 2 | A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer | October 1, 2018 | August 24, 2021 |
| NCT01379807 | Unknown status | Phase 2 | Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | December 2010 | December 2015 |
| NCT02193594 | Unknown status | Phase 2/Phase 3 | Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma | January 2014 | May 2020 |
| NCT00763646 | Unknown status | Phase 2 | Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma | April 2007 | |
| NCT05019794 | Unknown status | Phase 2 | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations | May 13, 2020 | December 30, 2023 |
| NCT04915807 | Unknown status | Real-world Data (RWD) of Ramucirumab Plus Paclitaxel | June 2021 | September 2023 | |
| NCT00964080 | Unknown status | Phase 1/Phase 2 | Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma | May 2009 | April 2015 |
| NCT02007148 | Unknown status | Phase 2 | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer | November 2013 | May 2022 |
| NCT03221400 | Unknown status | Phase 1/Phase 2 | PEN-866 in Patients With Advanced Solid Malignancies | August 29, 2017 | June 2023 |
| NCT04263870 | Unknown status | Phase 2 | Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | March 2020 | October 2021 |
| NCT03349866 | Unknown status | Phase 2 | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction | November 30, 2017 | November 30, 2020 |
| NCT03368131 | Unknown status | Phase 2 | Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study | December 1, 2017 | December 31, 2020 |
| NCT03986385 | Unknown status | Phase 3 | Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction | June 1, 2019 | January 31, 2021 |
| NCT03966118 | Unknown status | Phase 2 | Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma | April 1, 2019 | September 2023 |
| NCT03592407 | Withdrawn | Phase 2 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer | July 1, 2018 | April 2020 |
| NCT03739801 | Withdrawn | Phase 1/Phase 2 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | April 6, 2020 | April 6, 2023 |
- Disase is a (Disease Ontology)
- DOID:0080375
- Cross Reference ID (Disease Ontology)
- NCI:C9296
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1332166
- Exact Synonym (Disease Ontology)
- adenocarcinoma of Cardioesophageal junction
- Disase Synonym (Disease Ontology)
- adenocarcinoma of gastroesophageal junction